Clonazepam is a long-acting benzodiazepine indicated for seizure disorders (particularly absence seizures and Lennox-Gastaut syndrome) and panic disorder. Its long half-life and potent anticonvulsant properties make it valuable for both neurological and psychiatric conditions requiring sustained therapeutic effects.
Clinical Overview
Primary Clinical Applications
Clonazepam is indicated for absence seizures, myoclonic seizures, Lennox-Gastaut syndrome, and panic disorder with or without agoraphobia. It is also widely used off-label for social anxiety disorder, restless leg syndrome, and various movement disorders due to its anxiolytic and muscle relaxant properties.
Mechanism and Clinical Benefits
Clonazepam enhances GABA activity at benzodiazepine receptors, providing potent anticonvulsant, anxiolytic, and muscle relaxant effects. Its long half-life (18-50 hours) allows for twice-daily dosing and provides sustained seizure protection and anxiety control throughout the day.
Clinical Considerations
The long duration of action reduces breakthrough symptoms and allows for less frequent dosing compared to shorter-acting benzodiazepines. However, the extended half-life also increases the risk of accumulation and makes withdrawal more challenging, requiring very gradual tapering when discontinuing treatment.
Key Clinical Points
Withdrawal seizures on abrupt cessation
Because clonazepam is itself an anticonvulsant, stopping abruptly risks withdrawal seizures in patients with and without epilepsy. Tapering must be very gradual, and the long half-life means the taper takes longer than expected.
Dosing differs greatly by indication
Panic disorder targets 0.5 to 4 mg daily, while seizure disorders may require up to 20 mg. A dose appropriate for one indication can be far outside the range for the other.
Behavioural disinhibition in children
Paradoxical disinhibition and aggression occur more often in paediatric patients and are easily misread as worsening of the underlying condition rather than an adverse drug effect.
Long half-life cuts both ways
Eighteen to fifty hours means fewer breakthrough symptoms and twice-daily dosing, but also accumulation with repeated dosing and a more protracted withdrawal course than shorter-acting agents.
Contraindicated in severe hepatic impairment
Also contraindicated in severe respiratory insufficiency, sleep apnoea syndrome, and acute narrow-angle glaucoma. Carries the class boxed warning for dependence and for respiratory depression with opioids.
Prescribing Information
Dosing & Administration
Seizure Disorders – Adults:
- Initial: 1.5 mg daily in 3 divided doses (0.5 mg three times daily)
- Titration: Increase by 0.5-1 mg every 3 days
- Maintenance: 4-8 mg daily in divided doses
- Maximum: 20 mg daily
Seizure Disorders – Children:
- Initial: 0.01-0.03 mg/kg/day in 2-3 divided doses
- Maintenance: 0.1-0.2 mg/kg/day
- Maximum: 0.05 mg/kg/day
Panic Disorder – Adults:
- Initial: 0.25 mg twice daily
- Target dose: 1 mg daily after 3 days
- Range: 0.5-4 mg daily
- Maximum: 4 mg daily
Administration:
- May take with or without food
- Divide daily dose into 2-3 administrations for seizures
- ODT formulation dissolves on tongue
Indications
- Lennox-Gastaut syndrome (adjunctive therapy)
- Absence seizures (petit mal)
- Myoclonic seizures
- Panic disorder with or without agoraphobia
Contraindications
- Hypersensitivity to benzodiazepines
- Severe respiratory insufficiency
- Sleep apnea syndrome
- Severe hepatic insufficiency
- Acute narrow-angle glaucoma
Warnings & Precautions
- Boxed Warning: Risk of abuse, misuse, dependence; respiratory depression with opioids
- Suicidal thoughts: Monitor for behavioral changes (anticonvulsant indication)
- Physical dependence: Risk increases with dose and duration
- Withdrawal seizures: Taper very gradually when discontinuing
- Respiratory depression: Enhanced with CNS depressants
- Cognitive impairment: May affect memory and concentration
- Falls risk: Particularly in elderly patients
Drug Interactions
- Opioids: Increased risk of respiratory depression and death
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Dangerous potentiation of effects
- CYP3A4 inhibitors: May increase clonazepam levels
- Phenytoin, carbamazepine: May decrease clonazepam levels
Adverse Reactions
Common (≥10%):
- Somnolence, dizziness, fatigue, ataxia
- Depression, memory impairment
Behavioral:
- Behavioral disinhibition, aggression (particularly in children)
Serious:
- Respiratory depression, severe withdrawal syndrome
Special Populations
- Elderly: Increased sensitivity, higher fall risk, start with lower doses
- Hepatic Impairment: Contraindicated in severe impairment
- Pregnancy: Category D – avoid in pregnancy
- Pediatric: Monitor for behavioral changes and developmental effects
- Long half-life: Very gradual tapering required when discontinuing
</u
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
